Biofrontera Inc.
BFRI
$-0.02
Change (1 day)
$3.90
Year High
$0.61
Year Low
Categories
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription cream for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
Biofrontera Inc. (BFRI) - Company Outlook
Company Outlook
| Year | Receivables | Debt | Liabilities | Assets | Current Assets |
|---|---|---|---|---|---|
| 2023 | 5.16 M | 4.06 M | 23.14 M | 27.93 M | 23.08 M |
| 2022 | 7.41 M | -15,862,000 | 27.01 M | 50.88 M | 43.14 M |
| 2021 | 3.78 M | -24,545,000 | 41.88 M | 53.22 M | 46.42 M |
| 2020 | 3.29 M | -8,080,000 | 18.31 M | 24.14 M | 19.58 M |
| 2019 | 4.79 M | 30.9 M | 58.93 M | 28.75 M | 23.47 M |